Apixaban investigational formulations 2025?

Short answer: Apixaban is currently marketed only as oral tablets (2.5 mg and 5 mg). There isn’t a widely publicized, approved investigational formulation of apixaban as of 2025. Public details on other formulations that have been studied are limited.

If you want, I can help by:
- Looking up current clinical trials or regulatory documents (e.g., ClinicalTrials.gov, FDA/EMA communications) for any apixaban formulations in development and summarize them.
- Outlining the types of investigational formulations that have been explored for DOACs in general (e.g., liquid oral forms, orally disintegrating tablets, alternative routes) and noting whether they’ve progressed for apixaban.
- Providing a focused answer if you have a specific trial, route, or formulation in mind.

Would you like me to search for the latest trials or regulatory filings related to apixaban formulations?